Sagimet Biosciences Inc. (SGMT) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $627.18M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $-77.00K; Retained Earnings (Accumulated Deficit)USD $-370.95M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $459.45M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $8.00K; Retained Earnings (Accumulated Deficit)USD $-357.00M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $457.61M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $120.00K; Retained Earnings (Accumulated Deficit)USD $-346.35M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Additional Paid in CapitalUSD $455.92M; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $117.00K; Retained Earnings (Accumulated Deficit)USD $-336.78M.
Sagimet Biosciences Inc. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Additional Paid in Capital USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Common Stock, Value, Issued USD |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $0.00 | $627.18M | $-77.00K | $-370.95M | $256.15M | (m) | 3 month · $3.69M | (m) |
| 2026-03-31 | $0.00 | $459.45M | $8.00K | $-357.00M | $102.46M | (m) | 3 month · $1.84M | (m) |
| 2025-12-31 | $0.00 | $457.61M | $120.00K | $-346.35M | $111.38M | (m) | 12 month · $6.45M | (m) |
| 2025-09-30 | $0.00 | $455.92M | $117.00K | $-336.78M | $119.25M | (m) | 3 month · $1.69M | (m) |
| 2025-06-30 | $0.00 | $453.95M | $76.00K | $-323.87M | $130.16M | (m) | 3 month · $1.60M | (m) |
| 2025-03-31 | (m) | $452.36M | $121.00K | $-313.49M | $138.99M | (m) | 3 month · $1.47M | (m) |
| 2024-12-31 | $0.00 | $450.88M | $230.00K | $-295.31M | $155.81M | (m) | 12 month · $5.29M | (m) |
| 2024-09-30 | (m) | $449.35M | $441.00K | $-279.11M | $170.68M | (m) | 3 month · $1.55M | (m) |
| 2024-06-30 | (m) | $447.80M | $-23.00K | $-264.49M | $183.29M | 3 month · $27.00K | 3 month · $1.45M | (m) |
| 2024-03-31 | (m) | $446.38M | $7.00K | $-256.37M | $190.02M | (m) | 3 month · $759.00K | (m) |
| 2023-12-31 | (m) | $340.78M | $30.00K | $-249.74M | $91.06M | (m) | 12 month · $4.99M | (m) |
| 2023-09-30 | (m) | $339.47M | (m) | $-241.59M | $97.88M | (m) | 3 month · $1.85M | (m) |
| 2023-06-30 | (m) | $36.83M | (m) | $-235.24M | $-198.41M | (m) | 3 month · $1.06M | $1.00K |
| 2023-03-31 | (m) | (m) | (m) | (m) | $-192.70M | (m) | 3 month · $767.00K | (m) |
| 2022-12-31 | (m) | $35.00M | $-84.00K | $-221.87M | $-186.95M | (m) | 12 month · $1.88M | $1.00K |
| 2022-09-30 | (m) | (m) | (m) | (m) | $-180.55M | (m) | 3 month · $389.00K | (m) |
| 2022-06-30 | (m) | (m) | (m) | (m) | $-173.42M | (m) | 3 month · $383.00K | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | $-166.59M | (m) | 3 month · $387.00K | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | $-158.26M | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |